Evotec Rides Megatrend In Outsourced Innovation By Buying Aptuit CRO
Executive Summary
Evotec's CEO tells Scrip that by buying the CRO Aptuit his combined group becomes a one-stop-shop for drug makers who are increasingly outsourcing their innovation efforts.
You may also be interested in...
Evotec Leverages Infectious Diseases Space With Sanofi R&D Deal
Evotec's CEO tells Scrip its pact with Sanofi to develop an infectious disease pipeline could offer a commercially viable approach to battling the global AMR crisis.
Deal Watch: CSL Behring's Calimmune Buy Builds On Its Base & Adds Platform Tech
Acquisition of gene therapy company Calimmune expands on CSL Behring's hematology franchise and fits rare disease business model, plus adds platform tech with wide application for CSL's portfolio.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.